Aquestive Therapeutics (NASDAQ:AQST) Earns “Outperform” Rating from Leerink Partners

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “outperform” rating reissued by Leerink Partners in a research note issued on Monday, Benzinga reports. They currently have a $12.00 price target on the stock, up from their prior price target of $10.00. Leerink Partners’ price objective points to a potential upside of 152.10% from the stock’s previous close.

AQST has been the topic of several other reports. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 12th. HC Wainwright boosted their target price on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $8.67.

Aquestive Therapeutics Stock Down 4.4 %

AQST opened at $4.76 on Monday. The stock has a market capitalization of $433.35 million, a price-to-earnings ratio of -11.33 and a beta of 2.84. The firm has a 50 day moving average price of $4.26 and a 200-day moving average price of $3.68. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $27,000. SG Americas Securities LLC purchased a new position in shares of Aquestive Therapeutics during the 1st quarter valued at $54,000. The Manufacturers Life Insurance Company bought a new position in Aquestive Therapeutics in the 2nd quarter worth $76,000. Financial Advocates Investment Management increased its stake in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares in the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.